These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 10073506)

  • 1. Genetic control of anticoagulation.
    Mannucci PM
    Lancet; 1999 Feb; 353(9154):688-9. PubMed ID: 10073506
    [No Abstract]   [Full Text] [Related]  

  • 2. Genetic susceptibility to hemorrhagic complications during warfarin therapy.
    Tabrizi AR; Freeman BD; Buchman TG; Zehnbauer BA
    Surgery; 2001 May; 129(5):645-6. PubMed ID: 11331459
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to rebuttal: Gene variants of the cytochrome P450 CYP2C9 affect oral anticoagulation with warfarin.
    Margaglione M; Brancaccio V; Ciampa A; Di Minno G
    Thromb Haemost; 2001 Sep; 86(3):938. PubMed ID: 11583336
    [No Abstract]   [Full Text] [Related]  

  • 4. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.
    Aithal GP; Day CP; Kesteven PJ; Daly AK
    Lancet; 1999 Feb; 353(9154):717-9. PubMed ID: 10073515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2C9*3 allelic variant and bleeding complications.
    Ogg MS; Brennan P; Meade T; Humphries SE
    Lancet; 1999 Sep; 354(9184):1124. PubMed ID: 10509530
    [No Abstract]   [Full Text] [Related]  

  • 6. Avoiding overanticoagulation: pharmacogenomics or pragmatism?
    Baglin T
    Thromb Haemost; 2001 May; 85(5):945-6. PubMed ID: 11372698
    [No Abstract]   [Full Text] [Related]  

  • 7. Major bleeding caused by warfarin in a genetically susceptible patient.
    Bloch A; Ben-Chetrit E; Muszkat M; Caraco Y
    Pharmacotherapy; 2002 Jan; 22(1):97-101. PubMed ID: 11794436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Warfarin dose requirement and CYP2C9 polymorphisms.
    Halkin H; Lubetsky A
    Lancet; 1999 Jun; 353(9168):1972-3. PubMed ID: 10371596
    [No Abstract]   [Full Text] [Related]  

  • 9. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment.
    Taube J; Halsall D; Baglin T
    Blood; 2000 Sep; 96(5):1816-9. PubMed ID: 10961881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Warfarin therapy in a patient homozygous for the CYP2C9 3 allele.
    Ablin J; Cabili S; Lagziel A; Peretz H
    Isr Med Assoc J; 2002 Feb; 4(2):139-41. PubMed ID: 11875991
    [No Abstract]   [Full Text] [Related]  

  • 11. CYP2C9 polymorphism and warfarin dose requirements.
    Daly AK; Day CP; Aithal GP
    Br J Clin Pharmacol; 2002 Apr; 53(4):408-9. PubMed ID: 11966680
    [No Abstract]   [Full Text] [Related]  

  • 12. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy.
    Furuya H; Fernandez-Salguero P; Gregory W; Taber H; Steward A; Gonzalez FJ; Idle JR
    Pharmacogenetics; 1995 Dec; 5(6):389-92. PubMed ID: 8747411
    [No Abstract]   [Full Text] [Related]  

  • 13. Leu208Val and Ile181Leu variants of cytochrome P450 CYP2C9 are not related to the acenocoumarol dose requirement in a Spanish population.
    Zarza J; Hermida J; Montes R; Alberca I; López ML; Rocha E
    Blood; 2002 Jul; 100(2):734. PubMed ID: 12123234
    [No Abstract]   [Full Text] [Related]  

  • 14. Mutations of the CYP2C9 gene and the response to warfarin.
    Yasar U; Oscarson M; Eliasson E; Sjöqvist F
    Surgery; 2001 Mar; 129(3):384. PubMed ID: 11231472
    [No Abstract]   [Full Text] [Related]  

  • 15. Extreme warfarin sensitivity in siblings associated with multiple cytochrome P450 polymorphisms.
    Tabrizi AR; McGrath SD; Blinder MA; Buchman TG; Zehnbauer BA; Freeman BD
    Am J Hematol; 2001 Jun; 67(2):144-6. PubMed ID: 11343389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers.
    Verstuyft C; Morin S; Robert A; Loriot MA; Beaune P; Jaillon P; Becquemont L
    Pharmacogenetics; 2001 Nov; 11(8):735-7. PubMed ID: 11692083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic modulation of oral anticoagulation with warfarin.
    Margaglione M; Colaizzo D; D'Andrea G; Brancaccio V; Ciampa A; Grandone E; Di Minno G
    Thromb Haemost; 2000 Nov; 84(5):775-8. PubMed ID: 11127854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for anticoagulation-related bleeding complications.
    Jolobe O
    QJM; 2008 May; 101(5):419. PubMed ID: 18344249
    [No Abstract]   [Full Text] [Related]  

  • 19. Interindividual variability in sensitivity to warfarin--Nature or nurture?
    Loebstein R; Yonath H; Peleg D; Almog S; Rotenberg M; Lubetsky A; Roitelman J; Harats D; Halkin H; Ezra D
    Clin Pharmacol Ther; 2001 Aug; 70(2):159-64. PubMed ID: 11503010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children.
    Takahashi H; Ishikawa S; Nomoto S; Nishigaki Y; Ando F; Kashima T; Kimura S; Kanamori M; Echizen H
    Clin Pharmacol Ther; 2000 Nov; 68(5):541-55. PubMed ID: 11103757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.